Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(43%)
Results Posted
50%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
1
14%
Ph phase_1
5
71%
Ph early_phase_1
1
14%

Phase Distribution

6

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Recruiting2
unknown1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (14.3%)
Phase 15 (71.4%)
Phase 21 (14.3%)

Trials by Status

unknown114%
completed229%
active_not_recruiting114%
terminated114%
recruiting229%

Recent Activity

3 active trials
Showing 5 of 7
active_not_recruitingphase_1

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

NCT06961786
completedphase_1

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

NCT04052334
completedphase_1

TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)

NCT03475134
recruitingphase_1

Immunotherapy for the Treatment of Advanced Solid Tumor

NCT03658785
recruitingphase_2

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

NCT03166397
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06961786Phase 1

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

Active Not Recruiting
NCT04052334Phase 1

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Completed
NCT03475134Phase 1

TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)

Completed
NCT03658785Phase 1

Immunotherapy for the Treatment of Advanced Solid Tumor

Recruiting
NCT03166397Phase 2

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Recruiting
NCT03347097Early Phase 1

Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme

Unknown
NCT03992326Phase 1

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7